Virological and clinical cure in COVID‐19 patients treated with hydroxychloroquine: A systematic review and meta‐analysis
Open Access
- 3 May 2020
- journal article
- review article
- Published by Wiley in Journal of Medical Virology
- Vol. 92 (7) , 776-785
Abstract
Following the demonstration of the efficacy of hydroxychloroquine against severe acute respiratory syndrome coronavirus 2 in vitro, many trials started to evaluate its efficacy in clinical settings. However, no systematic review and meta‐analysis have addressed the issue of the safety and efficacy of hydroxychloroquine (HCQ) in coronavirus disease 2019. We conducted a systematic review and meta‐analysis with the objectives of evaluation of safety and efficacy of HCQ alone or in combination in terms of “time to clinical cure,” “virological cure,” “death or clinical worsening of disease,” “radiological progression,” and safety. RevMan was used for meta‐analysis. We searched 16 literature databases out of which seven studies (n = 1358) were included in the systematic review. In terms of clinical cure, two studies reported possible benefit in “time to body temperature normalization” and one study reported less “cough days” in the HCQ arm. Treatment with HCQ resulted in less number of cases showing the radiological progression of lung disease (odds ratio [OR], 0.31, 95% confidence interval [CI], 0.11‐0.9). No difference was observed in virological cure (OR, 2.37, 95% CI, 0.13‐44.53), death or clinical worsening of disease (OR, 1.37, 95% CI, 1.37‐21.97), and safety (OR, 2.19, 95% CI, 0.59‐8.18), when compared with the control/conventional treatment. Five studies reported either the safety or efficacy of HCQ + azithromycin. Although seems safe and effective, more data are required for a definitive conclusion. HCQ seems to be promising in terms of less number of cases with radiological progression with a comparable safety profile to control/conventional treatment. We need more data to come to a definite conclusion.Keywords
This publication has 19 references indexed in Scilit:
- Of chloroquine and COVID-19Antiviral Research, 2020
- In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)Clinical Infectious Diseases, 2020
- Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitroCell Research, 2020
- Bi-directional differentiation of single bronchioalveolar stem cells during lung repairCell Discovery, 2020
- Therapeutic options for the treatment of 2019-novel coronavirus: An evidence-based approachIndian Journal of Pharmacology, 2020
- A systematic review showed more consideration is needed when conducting nonrandomized studies of interventionsJournal of Clinical Epidemiology, 2020
- Risperidone for children and adolescents with autism spectrum disorder: a systematic reviewNeuropsychiatric Disease and Treatment, 2018
- ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventionsBMJ, 2016
- Chloroquine Treatment Enhances Regulatory T Cells and Reduces the Severity of Experimental Autoimmune EncephalomyelitisPLOS ONE, 2013
- Chloroquine is a potent inhibitor of SARS coronavirus infection and spreadVirology Journal, 2005